The safety profile of PDE4i, described in this review, and their selective inhibition of monocyte-derived TNF-α, identify them as potantially efficacious adjunctive drugs to be used with antibiotics for the successful treatment of human TBM. The gene discussed is TNF; the disease is meningeal tuberculosis.